Binimetinib + Encorafenib for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

+4 other locations

Overseen byAndrew E Hendifar

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Academic and Community Cancer Research United

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial studies how well the combination of binimetinib and encorafenib works in treating patients with pancreatic cancer that has a specific genetic mutation. These medications aim to stop cancer cells from growing by blocking certain enzymes they need. The trial targets patients whose cancer may not respond well to usual treatments. Encorafenib and binimetinib have shown substantial antitumor activity in melanoma, particularly in combination therapy.

Research Team

Andrew E Hendifar

Principal Investigator

Academic and Community Cancer Research United

Eligibility Criteria

This trial is for adults with pancreatic cancer that has a specific mutation (BRAF V600E). Participants must have had previous treatment, be able to swallow pills, and provide consent. They should not be pregnant or nursing and must agree to use contraception. People with certain health conditions or those taking prohibited medications are excluded.

Inclusion Criteria

Your local pathology lab has confirmed that you have pancreatic cancer.

Women who could become pregnant need to have a negative pregnancy test within 7 days before joining the study.

You have a specific BRAF V600E mutation in your tumor.

See 16 more

Exclusion Criteria

Pregnant women

Nursing women

Men or women of childbearing potential who are unwilling to employ adequate contraception

See 24 more

Treatment Details

Interventions

Binimetinib and Encorafenib (Kinase Inhibitor)

Trial OverviewThe effectiveness of two drugs, Binimetinib and Encorafenib, is being tested on patients with pancreatic cancer carrying the BRAF V600E mutation. The study aims to see if these drugs can stop tumor growth better than standard treatments by blocking enzymes needed for cell growth.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (encorafenib, binimetinib)Experimental Treatment2 Interventions

Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.